Renato Mastrangeli1, Maria Concetta Audino1, Steve Marquis Fernandes2

  • 1Global CMC Development, CMC Science & Intelligence, Merck Serono S.p.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Guidonia Montecelio, Rome, Italy.

PubMed
概括

开发可持续的重组蛋白疗法需要将化合物设计与过程优化整合起来. 这种方法尽量减少浪费,降低成本,并扩大获得创新药物的机会,这对于未来的生物治疗竞争力至关重要.